Transgene Biotek Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	2.11	2.61	2.35	0.55	0.87
Revenue Growth (YoY)	-18.99%	10.98%	326.32%	-36.44%	-48.87%
Cost of Revenue	-	-	0.03	0.66	-0.45
Gross Profit	2.11	2.61	2.32	-0.11	1.32
Selling, General & Admin	1.47	3.15	3.18	3.04	2.93
Other Operating Expenses	6.07	10.68	5.2	7.38	3
Operating Expenses	9.54	14.77	9.3	59.91	105.17
Operating Income	-7.43	-12.16	-6.98	-60.03	-103.85
Interest Expense	-10.6	-2.44	-1.4	-1.81	-2.29
Other Non Operating Income (Expenses)	1.5	1.75	1.75	1.75	1.75
EBT Excluding Unusual Items	-16.53	-12.84	-6.63	-60.09	-104.39
Other Unusual Items	-	6.08	0.07	-	0.37
Pretax Income	-16.53	-6.76	-6.56	-60.09	-104.02
Net Income	-16.53	-6.76	-6.56	-60.09	-104.02
Net Income to Common	-16.53	-6.76	-6.56	-60.09	-104.02
Shares Outstanding (Basic)	76	76	76	76	76
Shares Outstanding (Diluted)	76	76	76	76	76
EPS (Basic)	-0.22	-0.09	-0.09	-0.79	-1.37
EPS (Diluted)	-0.22	-0.09	-0.09	-0.79	-1.37
Free Cash Flow	-0.11	-5.04	0.05	-0.01	0.98
Free Cash Flow Per Share	-0.00	-0.07	0.00	-	0.01
Gross Margin	100.00%	100.00%	98.72%	-20.33%	152.09%
Operating Margin	-351.61%	-466.40%	-297.32%	-10894.01%	-11979.30%
Profit Margin	-782.62%	-259.34%	-279.06%	-10904.90%	-11998.40%
Free Cash Flow Margin	-5.35%	-193.21%	1.96%	-2.36%	112.81%
EBITDA	-5.44	-11.23	-6.06	-10.53	-4.61
EBITDA Margin	-257.34%	-	-258.02%	-	-
D&A For EBITDA	1.99	0.93	0.92	49.5	99.24
EBIT	-7.43	-12.16	-6.98	-60.03	-103.85
EBIT Margin	-	-	-297.32%	-	-
Revenue as Reported	3.61	10.44	4.18	2.31	2.99
Advertising Expenses	-	0.01	0.02	0.02	0.04